Neogenomics (NEO) Total Current Liabilities (2016 - 2025)
Neogenomics' Total Current Liabilities history spans 16 years, with the latest figure at $88.3 million for Q4 2025.
- For Q4 2025, Total Current Liabilities fell 70.69% year-over-year to $88.3 million; the TTM value through Dec 2025 reached $88.3 million, down 70.69%, while the annual FY2025 figure was $88.3 million, 70.69% down from the prior year.
- Total Current Liabilities reached $88.3 million in Q4 2025 per NEO's latest filing, down from $97.9 million in the prior quarter.
- In the past five years, Total Current Liabilities ranged from a high of $301.2 million in Q4 2024 to a low of $67.8 million in Q1 2021.
- Average Total Current Liabilities over 5 years is $129.4 million, with a median of $92.8 million recorded in 2021.
- The largest YoY upside for Total Current Liabilities was 264.61% in 2025 against a maximum downside of 70.69% in 2025.
- A 5-year view of Total Current Liabilities shows it stood at $87.2 million in 2021, then rose by 3.1% to $89.9 million in 2022, then grew by 7.09% to $96.3 million in 2023, then soared by 212.8% to $301.2 million in 2024, then plummeted by 70.69% to $88.3 million in 2025.
- Per Business Quant, the three most recent readings for NEO's Total Current Liabilities are $88.3 million (Q4 2025), $97.9 million (Q3 2025), and $100.1 million (Q2 2025).